Summary: In patients with diabetic peripheral neuropathy, the addition of empagliflozin 10 mg daily significantly reduced HbA1c, fasting blood glucose, and serum creatinine levels, while improving nerve conduction velocity and eGFR compared to a placebo group continuing their existing diabetes regimen, though it was associated with no reported significant adverse effects in this study. PICO Description Population Adult patients diagnosed with type 2 diabetes and confirmed diabetic peripheral neuropathy based on the Michigan Neuropathy Screening Instrument. Intervention Addition of empagliflozin 10 mg once daily to the patients’ existing diabetes treatment regimen for 20 weeks. Comparison Placebo added to the current…
Author: FWA
Summary: In patients with type 2 diabetes mellitus (T2DM) and cognitive decline, Huayu Tongluo moxibustion combined with routine hypoglycemic treatment significantly improved cognitive function and reduced insulin resistance compared to routine hypoglycemic treatment alone (waiting moxibustion group), though it was associated with no reported side effects. PICO Description Population Ninety adult patients diagnosed with type 2 diabetes mellitus (T2DM) and exhibiting cognitive decline. Intervention Huayu Tongluo moxibustion applied every other day for 12 weeks at Baihui (GV20), Shenting (GV24), and Dazhui (GV14) in addition to standard hypoglycemic therapy. Comparison Routine hypoglycemic treatment alone (waiting moxibustion group), without active moxibustion intervention…
Summary: In people living with HIV, diabetes, and hypertension in sub-Saharan Africa, integrated community-based care significantly improved management of these chronic conditions compared to integrated facility-based care, though it was associated with challenges related to implementation and some side effects consistent with treatment regimens. PICO Description Population Adults living with HIV, diabetes, and hypertension in Tanzania and Uganda, sub-Saharan Africa. Intervention Integrated community-based care involving coordinated chronic disease management delivered outside health facilities. Comparison Integrated facility-based care managing HIV, diabetes, and hypertension within health centers and hospitals. Outcome Community-based care significantly improved clinical outcomes and patient retention in care compared…
Summary: In adults with type 1 diabetes, metformin (1500 mg daily for 26 weeks) did not significantly reduce hepatic insulin resistance compared to placebo, though it was associated with no increase in hypoglycemia or ketoacidosis. PICO Description Population Adults with type 1 diabetes (n = 40), assessed for insulin resistance compared to adults without diabetes (n = 20); 37 participants with type 1 diabetes completed a 26-week randomized controlled trial. Intervention Metformin 1500 mg daily for 26 weeks, with evaluation of insulin resistance via hyperinsulinemic-euglycemic clamp technique. Comparison Placebo for 26 weeks in adults with type 1 diabetes. Outcome No…
Summary: In patients with chronic coronary artery disease (CAD), oral beetroot capsule supplementation significantly improved serum omega-3 fatty acids, decreased pro-oxidant markers like total oxidant status (TOS) and myeloperoxidase (MPO), and modulated fatty acid ratios (SFAs/PUFAs and PA/OA) compared to placebo and standard treatment over four weeks, though it was associated with no reported adverse effects in this analysis. PICO Description Population Adults (both male and female) with chronic coronary artery disease (CAD), participating in a randomized controlled trial over a 4-week period. Intervention Supplementation with beetroot capsules alone or in combination with vitamin C. Comparison Placebo/control group receiving standard…
The CREDENCE trial demonstrated that canagliflozin reduced the composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death by 30% in patients with type 2 diabetes and albuminuric chronic kidney disease, becoming the first dedicated renal outcomes trial to demonstrate that an SGLT2 inhibitor could substantially slow the progression of diabetic nephropathy.
Summary: In overweight and obese adults undergoing caloric restriction, twice-daily supplementation with exogenous β-hydroxybutyrate (BHB) mineral salts significantly reduced fat mass and improved body composition through lean mass preservation compared to placebo (maltodextrin), both groups under the same hypocaloric diet, though it was associated with no adverse metabolic side effects. PICO Description Population Overweight and obese adults participating in an 8-week caloric restriction regimen. Intervention Twice-daily oral administration of racemic β-hydroxybutyrate (BHB) mineral salts alongside a modest hypocaloric diet. Comparison Placebo group receiving twice-daily maltodextrin alongside the same hypocaloric diet. Outcome Within-group analysis of the BHB group showed significant fat…
Summary: In patients with diabetic peripheral neuropathy (DPN), tibial nerve neurodynamic techniques (NDTs) significantly reduced neuropathy severity and improved quality of life and range of motion compared to sham NDTs combined with basic complementary treatment, though it was associated with no changes in nerve conduction parameters or widespread mechanosensitivity improvement. PICO Description Population Adults diagnosed with diabetic peripheral neuropathy (DPN), confirmed by electrodiagnostic and laboratory assessments. Intervention Real tibial nerve neurodynamic techniques (NDTs) in combination with a standardized basic complementary treatment. Comparison Sham NDTs delivered alongside the same basic complementary treatment provided to the intervention group. Outcome Significant reductions in…
The DECLARE-TIMI 58 trial demonstrated that dapagliflozin did not reduce 3-point MACE compared with placebo but significantly reduced the composite of cardiovascular death or hospitalisation for heart failure, driven entirely by a 27% reduction in heart failure hospitalisation, in the largest and most broadly representative SGLT2 inhibitor cardiovascular outcomes trial conducted to date.
Summary: In adults with type 1 diabetes and chronic kidney disease (CKD), finerenone treatment significantly reduced the urinary albumin-to-creatinine ratio compared to placebo, though it was associated with potential side effects related to mineralocorticoid receptor antagonism (such as hyperkalemia). PICO Description Population Adults diagnosed with type 1 diabetes mellitus complicated by chronic kidney disease. Intervention Administration of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, dosage as per clinical protocol. Comparison Placebo treatment administered under identical conditions. Outcome Finerenone significantly reduced urinary albumin-to-creatinine ratio compared to placebo, indicating improved kidney function and reduced disease progression risk; associated adverse effects include hyperkalemia and…